INTRODUCTION {#S1}
============

Understanding gene expression patterns in response to chemoradiotherapy is crucial to the successful treatment of cancer. Recent emerging technologies permitted the development of targeted therapies for a variety of cancers^[@R1]^. However, most of these therapies target DNA transcription initiation factors or signaling kinases. Interestingly, studies demonstrated that during chemotherapy, post-transcriptional control of messenger RNA (mRNA) stability/turnover is altered, this alteration offers a promising target for the development of new therapeutics^[@R2]^. For instance, RNA-binding proteins (RBPs) thought to be involved in controlling the expression of mRNAs that encode proteins responsible for cell death, consequently altering treatment efficacy in cancer^[@R3]--[@R5]^. RBP-mediated cell death is considered an additional checkpoint for cancer treatment. However, a mechanistic link between RBP-mediated halting of cancer cell growth and efficacy of treatment has not been thoroughly studied.

Human antigen R (HuR), belongs to the family of ELAV (embryonic lethal, abnormal vision) proteins, known to regulate cellular development and immune functions^[@R6],\ [@R7]^. In cancer, HuR regulates the mRNAs encoding proteins involved in cell proliferation, angiogenesis, apoptosis and cell migration^[@R8]^. Although HuR is an extensively studied RBP, HuR mediated control of apoptosis in cancer is poorly understood. Under lethal cellular stress like hypoxia or ionizing radiation, caspase-3 cleaves HuR and the resulting HuR cleavage products promote cell death^[@R9]--[@R11]^.

The cellular apoptotic response is controlled by the intrinsic or extrinsic pathway, depending on the stress response. The intrinsic pathway is triggered by disruption of the mitochondrial membrane potential by Bcl protein family members and dysregulation of this pathway induces cancer^[@R12]^. In the extrinsic pathway, extracellular death ligands like Fas L^[@R13]^ bind to cell-surface receptors stimulating caspase-8 cleavage and subsequently caspase-3 activation. Caspases are inhibited by several proteins involved in cell proliferation^[@R14]^. For example, cyclooxygenases (COX), also known as prostaglandin G/H synthases, enzymatically convert arachidonic acid to prostaglandins and thromboxane A2. There are two known isoforms of COX enzymes: COX-1 (alias PTGS1) and COX-2 (alias PTGS2)^[@R15]^. COX-2 is overexpressed in several cancers, including oral squamous cell carcinoma^[@R16]--[@R22]^. Interestingly, overexpressed COX-2 blocked caspase-3 activation, and subsequent inhibition of COX-2 activity by celecoxib induced apoptosis^[@R23]^. HuR is known to control the expression of *COX-2* mRNA in multiple cancers through interaction with AU-rich elements in the 3\' untranslated region^[@R24]--[@R27]^. Although these observations support that HuR controls COX-2 expression in cancer, the molecular mechanism of HuR-mediated COX-2 promotion of tumor growth under chemoradiotherapy remain elusive. In the present study, we define a previously unidentified role for COX-2 in regulating caspase-3 and HuR cleavage in oral cancer cells. Here we show that, inhibition of COX-2 activity by celecoxib, promotes caspase-3 activation and HuR cleavage, which destabilizes *COX-2* mRNA. Our observations suggest that disruption of the COX-2/HuR reciprocal feedback loop, can sensitize paclitaxel-resistant oral cancer cells to treatment.

Results {#S2}
=======

Cleavage of HuR is cancer cell specific {#S3}
---------------------------------------

We previously showed that treatment of hypoxia and ionizing radiation (IR) promoted the cleavage of HuR through active caspase-3^[@R9],\ [@R10]^. Here, in order to determine if chemo- and radio-therapy promoted the cleavage of HuR in drug resistant and sensitive oral cancer cells, we treated 74B oral cancer cells with a variety of cytotoxic agents and IR. Treatment of paclitaxel, doxorubicin and IR induced the cleavage of HuR; however, cisplatin did not promote HuR cleavage even at the highest concentration of 10µM ([Figure 1A](#F1){ref-type="fig"} and [S1A](#SD1){ref-type="supplementary-material"}). Next, to extend our observation, we monitored the cleavage of HuR during paclitaxel treatment of primary (nomenclature of A) and recurrent (nomenclature of B) oral cancer cells. HuR was preferentially cleaved in the recurrent cell lines, compared to the primary cell lines; one exception was 22A cells which exhibited less cleavage of HuR compared to 22B cells ([Figure 1B](#F1){ref-type="fig"}). Based on the pattern of cleavage of HuR, we selected two primary oral cancer cell lines UMSCC-11A and UMSCC-74A and two recurrent cell lines UMSCC-11B and UMSCC-74B for further analysis. To determine if the cleavage of HuR associated with active caspase-3, paclitaxel treated cells were probed for active caspase-3 and HuR. As shown in [Figure 1C](#F1){ref-type="fig"}, recurrent cell lines 11B and 74B exhibited strong cleavage of HuR and caspase-3 compared to 11A cells. In contrast, primary 74A cells showed minimal HuR cleavage in association with activation of caspase-3 compared to 74B cells. Previous observations indicated that the cleavage of HuR is a cytoplasmic event controlled by active caspase-3^[@R28]^, hence, we monitored the subcellular localization of HuR under paclitaxel. As shown in [Figure 1D](#F1){ref-type="fig"}, presence of HuR was noted in both the cytoplasm and nucleus of 11A and 74B cells with or without treatment of paclitaxel. Although the cytoplasmic presence of HuR was observed in both 11A and 74B cells, the lack of active caspase-3 in 11A cells failed to cleave HuR compared to 74B cells under paclitaxel ([Figure 1C--D](#F1){ref-type="fig"}). Collectively, these data suggest that paclitaxel mediated cleavage of HuR associated with active caspase-3 in cancer cells.

Next, to determine whether the observed changes in caspase-3 and HuR altered the rate of cell death under paclitaxel treatment, the percentage of apoptotic cells were quantified. As shown in [Figure 1E](#F1){ref-type="fig"}, paclitaxel treated primary 11A and 74A cells ([Figure S1B](#SD1){ref-type="supplementary-material"}) exhibited reduced rate of apoptosis (from \~3% to 9%, 74A cells exhibits \~15 to 25%, [Figure S1B](#SD1){ref-type="supplementary-material"}) compared to 74B cells (\~17 % to 70%; [Figure 1E](#F1){ref-type="fig"}). These data indicated that paclitaxel induced apoptosis in recurrent 74B cells was significantly higher than primary 11A and 74A oral cancer cells. To test if the altered apoptotic rates were mediated through HuR, we silenced HuR and quantified the number of apoptotic cells under paclitaxel. As shown in [Figure 1F](#F1){ref-type="fig"}, silencing of HuR by shRNA reduced the rate of cell death in 74B cells, indicating that HuR partly facilitated apoptosis in paclitaxel treated cells. We did not detect a significant change in the apoptotic rate of 11A cells ([Figure 1F](#F1){ref-type="fig"}), in part due to inactivation of caspase-3 under paclitaxel. Altogether, our findings indicated that paclitaxel induced caspase-3 activation, promoted HuR cleavage and enhanced apoptosis in recurrent cancer cells compared to primary oral cancer cells.

HuR controls *COX-2* expression in oral cancer cells {#S4}
----------------------------------------------------

Our previous observation demonstrated that the non-cleavable isoform of HuR (HuR-D226A), increased cell proliferation compared to the full-length or cleavable isoforms of HuR^[@R10]^. The presence of cellular non-cleavable HuR and inactive caspase-3 in primary tumor cells compared to recurrent cells during paclitaxel treatment suggested that non-cleavable HuR and inactive caspase-3 may facilitate cell proliferation and drug resistance ([Figure 1C](#F1){ref-type="fig"}). To further assess this, we determined the levels of HuR target mRNAs encoding proteins involved in cell proliferation such as *COX-2, c-MYC, c-JUN* and *IL-8* in 11A and 74B cells. These mRNAs contain AU-rich elements, HuR recognition sequence motifs, in their 3\' untranslated region (UTR). Most HuR target mRNAs were down regulated in 74B cells during paclitaxel treatment ([Figure 2A](#F2){ref-type="fig"}). In contrast, 11A cells exhibited reduced levels of *c-MYC*, *c-JUN* and *IL-8* mRNAs but significant upregulation of *COX-2* mRNA under paclitaxel treatment ([Figure 2B](#F2){ref-type="fig"}). Next, to determine whether the observed changes in COX-2 and other mRNAs were due to direct association with HuR, we performed ribonucleoprotein (RNP) IP on control and paclitaxel-treated cells using an antibody against HuR. The HuR-associating mRNAs were then measured by RT-qPCR. As shown in [Figure 2A and 2B](#F2){ref-type="fig"}, we observed a strong association of COX-2 mRNA with HuR in 11A cells (\~68 fold) compared to 74B cells (\~18 fold) after treatment with paclitaxel ([Figure 2C](#F2){ref-type="fig"}, 74B cells and 2D, 11A cells). Interestingly, the basal COX-2 protein levels in 11A cells is \~3.0 fold higher than 74B cells ([Figure 2E](#F2){ref-type="fig"}). In addition, like mRNA expression, the COX-2 protein levels were increased 2.0 fold in paclitaxel treated 11A cells compared to control cells. In contrast, COX-2 protein level showed a moderate decrease from 1.0 fold 0.9 fold after paclitaxel treatment in 74B cells ([Figure 2E](#F2){ref-type="fig"}). The remaining mRNAs c-myc, c-Jun and IL-8 mRNAs were also bound with HuR in IP samples.

Next, to determine if the alteration of COX-2 protein during paclitaxel treatment was due to changes in *COX-2* mRNA stability, we treated both cell lines with paclitaxel and estimated the half-life (t~1/2~) of the mRNA under actinomycin-D (ActD). As shown in [Figure 2F--G](#F2){ref-type="fig"}, after paclitaxel treatment *COX-2* mRNA was unstable in 74B cells (t~1/2~ decreased from \~6:30 hrs to \~4 hrs) compared to 11A cells (t~1/2~ increased from \~5 hrs to \~ 7:20 hrs), indicating that paclitaxel promotes the stability of *COX-2* mRNA in 11A cells. To directly assess whether *COX-2* mRNA expression is controlled by HuR, we silenced HuR and evaluated *COX-2* mRNA levels using RT-qPCR. The shRNA-mediated silencing of HuR reduced the relative expression of *COX-2* mRNA and protein expression in both cell lines ([Figure 3A--B](#F3){ref-type="fig"}). Next, the half-life of COX-2 mRNA was measured in HuR silenced 74B and 11A cells. In shcontrol 74B and 11A cells, *COX-2* mRNA t~1/2~ was more than 6 hours, while in HuR silenced cells, the half-life was reduced to approximately 4 hours ([Figure 3C--D](#F3){ref-type="fig"}), indicating that HuR directly controls *COX-2* stability in both cell lines. Collectively, these data demonstrated that HuR is a dominant protein controlling *COX-2* mRNA expression in cancer cells, but the observed difference in basal COX-2 protein expression between 74B and 11A cells may be due in part to additional regulatory pathways.

Inhibition of COX-2 by celecoxib promotes active caspase-3 and HuR cleavage {#S5}
---------------------------------------------------------------------------

Increased COX-2 expression is correlated with tumor cell resistance to chemotherapeutic drugs^[@R29]^. Inhibition of COX-2 activity by celecoxib, resulted in increased apoptosis, activation of caspase-3, caspase-9 and PARP cleavage^[@R23]^. Hence, we sought to determine whether selective inhibition of COX-2 with celecoxib during paclitaxel treatment altered COX-2 activity, using a COX-2 enzymatic assay^[@R30]^. As shown in [Figure 4A](#F4){ref-type="fig"}, basal COX-2 activity in 11A cells was significantly higher compared to 74B cells. Upon treatment with both celecoxib and paclitaxel, we observed a significant reduction in COX-2 activity in 11A cells in comparison to 11A cells treated with paclitaxel alone ([Figure 4A](#F4){ref-type="fig"}). To determine if this combinatorial therapy in 11A cells induced caspase activation and HuR cleavage, the cells were treated for 2 hrs with paclitaxel and celecoxib, and protein expression was measured by Western blot. As expected, inhibition of COX-2 by celecoxib in association with paclitaxel treatment, promoted the cleavage of caspase-3 and HuR after 2 hours in 11A cells ([Figure 4B](#F4){ref-type="fig"}). In addition, 74B cells treated with paclitaxel alone for 2 hours did not exhibit cleavage of HuR but both celecoxib and paclitaxel treatment promoted the cleavage of HuR ([Figure 4B](#F4){ref-type="fig"}). In both cell lines, treatment of celecoxib alone failed to induce caspase-3 or HuR cleavage. To test whether the observed changes in the cleavage of caspase-3 and HuR altered the rate of apoptosis during celecoxib and paclitaxel treatment, we quantified the rate of apoptosis in both cell lines. As shown in [Figure 4C](#F4){ref-type="fig"}, after 2 hours of celecoxib and paclitaxel treatment, the primary 11A cells exhibited increased apoptosis (\~7% to \~18%) compared to paclitaxel alone (\~3 % to \~7%; [Figure 4C--D](#F4){ref-type="fig"}). In addition, the apoptotic rate in celecoxib and paclitaxel treated 74B cells increased (\~15% to \~35%) compared to paclitaxel alone ([Figure 4C--D](#F4){ref-type="fig"}). Collectively, these data suggest that combinatorial treatment with celecoxib and paclitaxel, is sufficient to induce HuR cleavage and activate apoptosis in COX-2 driven drug resistant oral cancer cells.

It has been reported that overexpression of HuR cleavage products induced cell death under stress^[@R11]^. In order to investigate whether HuR cleavage product-1 and paclitaxel are sufficient to induce apoptosis by activating caspase-3 in primary oral cancer cells, we transiently overexpressed the cleaved HuR isoform GFP-CP1 in 11A and 74A cells. As expected, we observed cleavage of both HuR and caspase-3 in paclitaxel treated GFP-CP1 overexpressing 11A and 74A cells after 16hrs (lane 4 and 8 in [Figure 4E](#F4){ref-type="fig"}); whereas, DMSO or paclitaxel treated GFP control cells and DMSO treated GFP-CP1 cells exhibited no cleavage of HuR and caspase-3 (lanes 1--3 and 5--7 in [Figure 4E](#F4){ref-type="fig"}). These data demonstrate that overexpression of HuR-CP1 in combination with paclitaxel may overcome drug resistance in oral cancer cells.

COX-2 overexpression and non-cleavable HuR promotes oral cancer tumorigenesis {#S6}
-----------------------------------------------------------------------------

To gain insights into the cancer promoting and drug resistance function of COX-2 and HuR *in vivo*, we subcutaneously injected equal number of 11A or 74B cells into the right and left flank of 4 week old nude mice and monitored tumor growth. When the tumor volume reached 25 mm^3^, we injected 100µL of DMSO and 20mg/kg of paclitaxel in 100µL of DMSO intra-tumorally on the left and right flank of nude mice respectively, carrying either 11A or 74B cell derived xenograft tumors. The paclitaxel was injected once every two days for 2 weeks or until the tumors reached 200 to 250 mm^3^ in volume. Paclitaxel treated 74B derived xenograft tumors exhibited a reduction in growth after 10 days of treatment compared to DMSO treated tumors ([Figure 5A](#F5){ref-type="fig"}). In contrast, there was no observed difference in tumor growth between DMSO and paclitaxel treated 11A derived xenograft tumors ([Figure 5B](#F5){ref-type="fig"}). However, paclitaxel and celecoxib treated 11A xenograft tumors exhibited a reduction in growth after 12 days of treatment compared to paclitaxel alone treated tumors ([Figure 5B](#F5){ref-type="fig"}). In agreement with our *in vitro* data, western blot analysis of paclitaxel treated 74B derived xenograft tumor samples showed HuR cleavage ([Figure 5C](#F5){ref-type="fig"}), whereas, DMSO treated 74B or 11A tumors and paclitaxel treated 11A tumors exhibited no cleavage of HuR ([Figure 5C](#F5){ref-type="fig"}). Next, we tested the cell proliferation marker Ki67 and angiogenesis marker CD31 in 74B and 11A derived xenograft tumors. Ki67 and CD31 staining was high in both 74B and 11A DMSO treated tumors and paclitaxel treated 11A tumors compared to paclitaxel treated 74B and paclitaxel/celecoxib treated 11A derived tumors ([Figure 5D](#F5){ref-type="fig"}, quantitative representation illustrated in [5E](#F5){ref-type="fig"}). To detect apoptosis in the tumors, we stained the tissues with TUNEL and measured cell death. As shown in [Figure 5F](#F5){ref-type="fig"}, both 74B paclitaxel and 11A paclitaxel/celecoxib treated tumors exhibited pronounced cell death compared to control tumors. Altogether, data from xenograft studies indicate that overexpression of COX-2 and non-cleavable HuR may control tumor growth and paclitaxel resistance of 11A cells *in vivo*.

HuR cleavage product-1 (HuR-CP1) specifically associates with mRNAs encoding proteins involved in cell death {#S7}
------------------------------------------------------------------------------------------------------------

HuR-CP1 and CP2 are known to promote apoptosis by altering the expression of apoptosis-associated ARE containing mRNAs^[@R11]^. To determine whether full-length HuR, HuR-CP1 and non-cleavable form of HuR (HuR-D226A) forms a complex with target mRNAs under IR, we have used RNP IP assay followed by high-throughput sequencing (HTS). [Figure 6A](#F6){ref-type="fig"} illustrates the methodology of RNP IP assays, HTS analysis and target enrichment analysis. First, 74B cells stably transfected with GFP-tagged HuR, HuR-CP1 and HuR-D226A isoforms were irradiated with ionizing radiation of 10Gy and cultured for 24 hours to promote cell death and cleavage of HuR ([Figure 6B](#F6){ref-type="fig"}). IR induced the cleavage of GFP-HuR-FL but did not promote the cleavage of GFP-HuR-D226A compared to control GFP expressing cells ([Figure 6B](#F6){ref-type="fig"}). Interestingly, overexpression of HuR-CP1 and HuR-FL minimizes the cleavage of cellular HuR possibly through competitive binding with caspase-3. Next, to determine if these isoforms of HuR bound with target mRNAs, we conducted RNP IP assay using anti-GFP antibody. The GFP-bound RNAs were extracted and subjected to HTS analysis. The mRNAs that were bound to GFP versus full-length HuR ([Table S1](#SD2){ref-type="supplementary-material"}), HuR-CP1 ([Table S2](#SD2){ref-type="supplementary-material"}) and HuR-D226A ([Table S3](#SD4){ref-type="supplementary-material"}) were compared with known HuR targets identified through PAR-CLIP^[@R31]^ ([Figure 6C](#F6){ref-type="fig"}). As shown in [Figure 6C](#F6){ref-type="fig"}, there are 644 target mRNAs bound to full-length HuR, HuR-CP1 and HuR-D226A isoforms, but more than 3000 targets associated with HuR-D226A isoform alone and only 26 targets were exclusively bound to HuR-CP1. These data suggest that HuR-D226A has an enhanced capability to bind RNA compared to HuR-CP1. Interestingly, HuR-CP1 associated with several target mRNAs encoding proteins noted to be involved in the cell death pathway ([Table 1](#T1){ref-type="table"} and [Figure 6D](#F6){ref-type="fig"}). Next, bioinformatic analysis revealed that mRNA sequences that bound with HuR contained several AREs in their 3\'UTR ([Figure 6E](#F6){ref-type="fig"}, S4). Thus, our findings indicate that HuR-CP1 specifically binds with mRNAs involved in cell death. Altogether, our model ([Figure 6F](#F6){ref-type="fig"}) illustrates that the overexpression of COX-2, blocks the cleavage of caspase-3 and HuR, thus promoting drug resistance.

Discussion {#S8}
==========

The regulation of post-transcriptional gene expression is always tightly associated with mRNA processing, transport, stability and translation. These processes are critical for precise control of gene expression and regulate several cancer biological pathways including cell death and proliferation. RBPs are the major determining factors that facilitate post-transcriptional gene expression. During cancer progression RBPs are post translationally modified and are involved in drug resistance. Here, we show that RBP HuR undergoes a post-translational modification which is integral to chemotherapeutic drug susceptibility in oral cancer cells. HuR control of *COX-2* mRNA expression is well-known. Multiple studies demonstrated that HuR directly associates with AU-rich elements present in the 3\' UTR of *COX-2* and controls *COX-2* stability and translation^[@R32]^. Overexpressed COX-2 protein is reported in multiple cancers, including colon,^[@R33]^ stomach,^[@R16]^ lung,^[@R17]^ esophagus,^[@R18]^ pancreas,^[@R18]^ bladder,^[@R34]^ prostate^[@R35]^ and oral cavity^[@R19]--[@R22]^. In oral cancer, expression of COX-2 is associated with tumor size and poor patient response to chemoradiation^[@R26]^. Based on our findings in this report, we establish that HuR controls *COX-2* mRNA stability in both 11A and 74B cells. In addition, activated caspase-3 promoted the cleavage of HuR during paclitaxel treatment in 74B cells; however, 11A cells, which exhibits increased levels of COX-2 protein, failed to cleave both caspase-3 and HuR. Interestingly, in support of these observations, HuR was reported to enhance *COX-2* mRNA stability in mammary epithelial cells treated with taxanes^[@R36]^. Altogether, our observations indicate that overexpression of COX-2 may play a positive role in cancer progression by promoting resistance to paclitaxel treatment, through blocking the activation and cleavage of caspase-3 and HuR, respectively.

Caspases are defined as either tumor suppressors or oncogenes by executing cell death in normal cells or undergo severe suppression in some cancers. For example, absence of caspase-3 was reported in multiple cancers including breast cancer tissues^[@R37]^, hepatocellular, and prostate carcinoma^[@R38]^. In addition, inactive caspase-3 was reported in both oral carcinoma and differentiated normal oral epithelial tissues^[@R39]^, but the molecular basis for this inactivation of caspase-3 was not known. Our results clearly indicate that overexpressed COX-2 inhibits the cleavage of caspase-3 and HuR in oral cancer cells. Taken together, the level of COX-2 and HuR can be used as an index for oral cancer patient prognosis and survival. Moreover, COX-2 and HuR may also be therapeutic targets for oral malignancy, particularly in patients who underwent chemotherapy that resulted in drug resistance.

HuR alters many biological functions in cancer cells which includes mediating apoptotic or anti-apoptotic responses.^[@R9],\ [@R40],\ [@R41]^. Post-translational modification of HuR may provide a mechanism to control the stability of mRNAs encoding proteins involved in the apoptosis pathway. For instance, HuR cleavage products are known to target several genes, such as Caspase-9, and control their mRNA stability and expression^[@R11]^. We assume that the apoptotic function of cleaved HuR in the form ofHuR-CP1, its associated target mRNAs and their coding proteins, may provide an opportunity to develop novel therapeutics. Based on our RNP IP analysis, we were able to identify HuR targets such as ING4^[@R42]^, RNF216^[@R43]^ and CDK11A^[@R44]^, which are associated with apoptosis suggesting a novel mechanism whereby HuR-CP1 initiates cell death by controlling a subset of mRNAs encoding apoptotic proteins. Furthermore, we have previously shown that HuR-CP1, inhibits *c-myc* mRNA translation under hypoxic lethal stress^[@R10]^.- In addition, reports postulate that HuR-CP1 binds with multiple protein partners and controls the cell death pathway^[@R28],\ [@R40]^. As HuR-CP1 impacts the cellular HuR cleavage ([Figure 6B](#F6){ref-type="fig"}), there is a strong possibility that HuR-CP1 could play a role in apoptotic pathway either as an initiator or competitor full length HuR to alter the cell death machinery. Hence, it would be interesting to identify HuR-CPs and their role in post-transcriptional gene regulation. Based on our RNP IP and transcriptome analysis, we were able to identify several novel HuR-CP1 regulons compared to full length HuR that could potentially impact apoptosis pathway.

Materials and Methods {#S9}
=====================

Cell lines and constructs {#S10}
-------------------------

The oral cancer cell lines were genotyped and authenticated as described^[@R45]^. The HuR isoforms tagged with GFP such as full-length HuR, HuR-D226A, HuR-CP1 (gift from Dr. Gallouzi laboratory, McGill University) have been previously described (27). The transfections of plasmids were conducted by using Lipofectamine-2000 (Life Technologies). For HuR transient silencing experiments, cells were transduced with either a scrambled shRNA or two different shRNAs targeting CDS and 3\'UTR of HuR (Sigma clones: TRCN0000017274 and TRCN0000276186).

Immunoblotting and Apoptosis assay {#S11}
----------------------------------

The cell lysates were separated by SDS--PAGE and followed by immunoblotting using antibodies against HuR (Santa Cruz, sc-5261), caspase-3 (Cell Signaling, 8G10) and COX-2 (One World Lab, 43977). Apoptosis assay was carried out based on manufacturer's protocol (Annexin V-PE apoptosis detection kit; Biovision, K128-100).

Cox-2 enzyme activity assay {#S12}
---------------------------

Cox-2 enzyme activity was assayed according to the manufacturer's protocol (Cayman Chemical Company, Michigan, USA). Briefly, either untreated, paclitaxel treated or paclitaxel and celecoxib treated cells were washed with HBSS and harvested with a rubber policeman. Cell pellets were sonicated in the presence of cold buffer (0.1M Tris-HCl, pH 7.8 containing 1mM EDTA) and centrifuged at 10,000 xg for 15 minutes at 4°C. The supernatant was used for the assay.

RNA Extraction, qRT-PCR and RNP analysis {#S13}
----------------------------------------

Total RNA was prepared from mice tissues and HNSCC cell lines using TRIzol (Qiagen). The qRT-PCR was conducted using ABI Step One Plus system with the SYBR Green qRT-PCR kit. The sequences of the primers were shown in [supplemental Table S1](#SD2){ref-type="supplementary-material"}. HuR RNP IP was performed as previously described^[@R46]^.

RNA sequencing (RNA-seq) and analyses {#S14}
-------------------------------------

100 ng of total RNA from RIP samples was used to prepare RNA-seq libraries using the TruSeq RNA Sample Prep Kit (Illumina, San Diego, CA), following the protocol described by the manufacturer. High throughput sequencing (HTS) was performed on an Illumina HiSeq2500 with each sample sequenced to a minimum depth of \~50 million reads using a paired end approach. The primary data analysis demanded that \>80% of the sequence data had a Phred score of 30 in accordance with Illumina quality control (QC) procedures. Secondary data analysis involved an RNAseq workflow to process the data. This enabled data validation and quality control, read alignment to the human genome (hg19) using TopHat2^[@R47]^, which indicated \>93% read mapping. Gene-level count data was extracted with HTSeq and DEseq2^48^ was utilized to uncover differential expression with robust statistical power. The workflow was executed on a OnRamp Bioinformatics Genomics Research Platform. Software versioning included FastQValidator v0.1.1a, Fastqc v0.11.3, Bowtie2 v2.1.0, TopHat2 v2.0.9, HTSeq v0.6.0 and DEseq v1.8.0. Transcript count data from the DESeq2 analysis of the samples was ranked based on the q-value from lowest to highest. FDR is the expected fraction of false positive tests among significant tests and was calculated using the Benjamini-Hochberg multiple testing adjustment procedure. Statistical analysis of pathways and gene ontology (GO) terms was carried as described by us previously^49,\ 50^. Venn diagrams were created using BioVenn^52^.

Accession numbers {#S15}
-----------------

Transcriptome fastq files have been deposited into GEO (Gene Expression Omnibus) and available using the GEO number GSE79477.

Experimental animals and xenograft studies {#S16}
------------------------------------------

Four week old athymic nude mice (Medical University of South Carolina Animal Husbandry) were used for the transplantation studies. The animal research was handled in accordance with the guidelines of the Institutional Animal Care and Use Committee. Both UMSCC-74B and UMSCC-11A cells were harvested a brief exposure to 0.02% EDTA and 0.05% trypsin. After blocking trypsinization the cells were washed with HBSS, then resuspended in complete medium and counted with a hemocytomer. Only suspensions containing viable cells (\>90%) were used for transplantation experiments. Approximately 4 million UMSCC-74B or UMSCC-11A cells were suspended in 100µl of complete medium containing 30% Matrigel (Corning) /and injected into the flank of the nude mice using a tuberculin syringe and 30-gauge needle, as described previously. A total of 16 mice (8 mice for 74B oral cancer cells group and 8 mice for 11A oral cancer cells group) received injection. Once in every two days, the weight of the mice and size of the tumors were measured. The formula V=1/2(L×W\^2) was used to calculate and measure the tumor volume. The maximum tumor volume of 25 mm^3^ as a cut off for the injection of paclitaxel and celecoxib. Mice with same sized tumors were randomized into two groups (n=5) group 1 (control) received 100µl DMSO and group 2 (paclitaxel treatment) received 20mg/kg paclitaxel dissolved in DMSO and injected intra-tumorally. Using a 5% level of significance, 80% power, and a standard deviation in tumor volume within a group, the two-sided t-test states those 5 animals per group is sufficient to detect a difference in tumor volume between any groups.

ARE motif analysis {#S17}
------------------

A basic R script based on the biomart R library was used to retrieve 3´UTR sequences. The longest 3´UTR sequences retrieved for each gene was scanned with a custom PERL script. The script performed a basic string match in scalar mode for ARE motifs in each 3´UTR. The script tracked the total number of 3´UTR matches and also counted the number of matches for each of the ARE motifs. These latter numbers were then charted with the standard Microsoft EXCEL 3D pie chart function.

Statistics {#S18}
----------

The graphical data are represented as mean ± S.D. We used student's *t* tests with equal variances to assess differences between means. *p* values \<0.05 were considered significant.

Supplementary Material {#SM}
======================
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![Caspase-3 mediated cleavage of HuR is cancer cell specific\
**A**) Western blot analysis of HuR cleavage patterns in UMSCC-74B cells treated with either DMSO, paclitaxel (0.5µM-1µM), cisplatin (1µM), doxorubicin (1µM) or 8Gy of ionizing radiation. **B**) Western blot analysis of HuR in multiple oral cancer cells treated with DMSO and paclitaxel (0.5µM). **C**) Western blot analysis of HuR and caspase-3 oral cancer cell lines treated with 0.5µM paclitaxel at the indicated time points. β-actin: loading control. **D**) Western blot analysis of HuR expression in nuclear/cytoplasmic fractionation during paclitaxel treatment. Lamin A/C (nuclear marker) and GAPDH (cytoplasmic marker). Representative western blots from three independent experiments are shown. **E**) Apoptotic rate of 74B and 11A cells treated with DMSO or 0.5µM paclitaxel for 24hrs. The percentage of early (bottom right quadrant) and late (top right quadrant) apoptotic cells are depicted in the scatter plots and bar graphs. Data represented as mean ± SD; N=3. **F**) Apoptotic rate between HuR silenced 74B and 11A cells under DMSO or 0.5µM paclitaxel treatment for 16hrs measured by flow cytometry. Data represented as mean ± SD; N=3.](nihms827240f1){#F1}

![HuR controls the expression of *COX-2* mRNA in primary and recurrent oral cancer cells\
**A--B)** The relative quantity of indicated mRNAs measured by qRT-PCR after 0.5µM paclitaxel treatment (24hrs) of 74B and 11A cells. Data represented as mean ± SD; N=3. **C--D**) Protein lysates of 74B and 11A cells were subjected to RIP IP followed by qRT-PCR analysis to measure the relative quantities of indicated mRNAs in HuR IP compared control IgG IP. GAPDH served as a loading control. **E**) Cox-2 protein expression in 74B and 11A cells after DMSO or 0.5µM paclitaxel treatment for 24hrs β-actin: loading control. Quantification of COX-2 protein levels in DMSO or 0.5µM paclitaxel treated 74B and 11A cells. **F--G**) The decay rate of *COX-2* mRNA in Paclitaxel treated 74B and 11A cells, respectively, was assessed by RT-qPCR after treatment with Actinomycin D. Values are the means ±SD (error bars) from three independent experiments.](nihms827240f2){#F2}

![HuR regulates COX-2 expression\
**A**) Relative quantity of *COX-2* mRNA in 74B and 11A cells post-HuR knockdown. Data represented as mean ± SD; N=3. **B**) Cox-2 and HuR expression in 74B and 11A cells in HuR silenced cells. β-actin: loading control. **C--D**) The decay rate of *COX-2* mRNA in HuR silenced 74B and 11A cells, respectively, was assessed by RT-qPCR after treatment with Actinomycin-D. Values are the means ±SD (error bars) from three independent experiments.](nihms827240f3){#F3}

![Celecoxib inhibits COX-2 enzymatic activity and promotes the cleavage of caspase-3 and HuR\
**A**) COX-2 enzyme activity was measured after treatment with DMSO, paclitaxel or paclitaxel/celecoxib (50µM) for 2 hrs. Data represented as mean ± SD; N=3. **B**) Western blot analysis of Cox-2, Caspase-3 and HuR in 74B and 11A cells treated with DMSO, paclitaxel or paclitaxel/celecoxib for 2 hrs. β-actin: loading control. Representative western blots from three independent experiments are shown. **C--D**) Measurement of apoptosis in 74B and 11A cells after DMSO, paclitaxel, celecoxib or paclitaxel/celecoxib treatment for 2 hrs. The percentage of early (bottom right quadrant) and late (top right quadrant) apoptotic cells are depicted in the scatter plots and bar graph. Data represented as mean ± SD; N=2. **E**) UMSCC-11A and 74A cells transiently over expressing GFP-CP1 were treated with DMSO or paclitaxel for 16 hrs. HuR and caspase-3 expression was analyzed by western blot. β-actin: loading control. Representative western blots of three independent experiments are shown.](nihms827240f4){#F4}

![COX-2 and non-cleavable HuR promotes tumorigenesis in vivo\
**A--B**) Growth of xenografts derived from 74B or 11A cells (4 million) after intra-tumoral injection of DMSO, paclitaxel (20mg/kg) or paclitaxel (20mg/kg)/celecoxib (20mg/kg) for 8--12 days. Data represented as mean ± SD; N=5. Representative tumor images (insert) from UMSCC-74B or UMSCC-11A cell derived xenografts. **C**) Total protein (60µg) from 74B and 11A xenografts treated with DMSO, paclitaxel (20mg/kg) or paclitaxel (20mg/kg)/celecoxib (20mg/kg) for 8--12 days and blots were probed for COX-2, HuR, active caspase-3 and β-actin. **D**) Immunohistochemical analysis of CD31 and Ki67 expression in 74B or 11A derived tumor xenografts tissues. **E**) Quantification of CD31 and Ki67 expression in 74B or 11A derived tumor xenograft tissues. Data represented as mean ± SD; N=2. **F**) Tumor sections of 74B and 11A xenografts treated with DMSO, paclitaxel (20mg/kg) or paclitaxel (20mg/kg)/celecoxib (20mg/kg) for 8--12 days were immunostained for TUNEL positive cells (red) and counterstained with DAPI (blue).](nihms827240f5){#F5}

![HuR-CP1 specifically associates with mRNAs encoding proteins involved in cell death\
**A**) Schematics showing the methodology used for identification of mRNA targets associated with different HuR isoforms in 74B cells post Ionizing radiation treatment. **B**) Western blot analysis of 74B cells stably expressing different isoforms of HuR post treatment with 10 Gy of Ionizing radiation. Total protein was extracted after 8hrs and the blots were probed for HuR, caspase 3 and β-actin. **C**) Venn diagram comparing mRNAs that are bound (more than 2 fold) to HuR-CP1, HuR-D226A and known HuR targets identified through PAR-CLIP^[@R47]^. **D**) Ingenuity Pathway analysis (IPA) network depicting HuR-CP1 associated mRNA targets involved in cell death pathway (as shown in [Table 1](#T1){ref-type="table"}). **E**) Pie-chart showing distribution of various AREs and HuR-binding sites in mRNA sequences. **F**) Model illustrating COX-2 control of HuR cleavage and drug resistance.](nihms827240f6){#F6}

###### 

Ingenuity Pathways Analysis (IPA) summary. The interactions of differently regulated genes obtained from the datasets representing HuR, HuR-D226A and HuR-CP1 bound mRNA profiles obtained from the RNAseq imported into the Ingenuity Pathway Analysis.

  --------------------------------------------------------------------------------------
  Biological Process    Diseases or Functions\                 p-value    Target\
                        Annotations                                       molecules
  --------------------- -------------------------------------- ---------- --------------
  Cell Death and\       apoptosis of basal epithelial\         9.26E-04   ING4
  Survival              prostate cells                                    

  Cell Death and\       formation of apoptotic bodies          8.31E-03   TAOK2
  Survival, Cellular\                                                     
  Assembly and\                                                           
  Organization                                                            

  Cell Death and\       cell viability of myeloma cell lines   2.97E-03   CDK11A, TNK2
  Survival                                                                

  Cell Death and\       cell death of breast cell lines        2.58E-03   ING4, TNK2
  Survival                                                                

  Cell Death and\       anoikis of fibroblast cell lines       1.29E-02   CDK11A
  Survival                                                                

  Cell Death and\       cell death of epithelial cell lines    3.79E-02   ING4, RNF216
  Survival                                                                
  --------------------------------------------------------------------------------------
